LG Life Sciences to seek European licenses

Published: 2004-06-29 06:56:00

Updated: 2004-06-29 06:56:00

LG Life Sciences said it has filed to the European Medicines Agency (EMEA) its biogeneric drugs, Utropin (human growth hormone) and Intermax-alpha (interferon alpha) for the first time in Korea.

The company hopes the EMEA's approval will be made available in the 4th quarter of 2005 after compl...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK